Adhesion molecules and the extracellular matrix as drug targets for glioma

Brain Tumor Pathology

Volumn 33, Issue 2, 2016, Pages 97-106

  Shimizu, Toshihiko ^a   Kurozumi, Kazuhiko ^a   Ishida, Joji ^a   Ichikawa, Tomotsugu ^a   Date, Isao ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Adhesion molecules; Angiogenesis; Extracellular matrix; Invasion; Malignant glioma

Indexed keywords

ANTINEOPLASTIC AGENT; BRAIN SPECIFIC ANGIOGENESIS INHIBITOR; CADHERIN; CCN PROTEIN; CD31 ANTIGEN; CELL ADHESION MOLECULE; CELL PROTEIN; CILENGITIDE; COLLAGEN; CYSTEINE RICH PROTEIN 61; FIBRONECTIN; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; LAMININ; NERVE CELL ADHESION MOLECULE; NEURADIAB; PROTEOGLYCAN; TENASCIN; THALIDOMIDE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; ANGIOGENESIS INHIBITOR; ANTIBODY; SNAKE VENOM;

CANCER SURVIVAL; CARCINOGENESIS; CELL ADHESION; DRUG EFFICACY; DRUG MECHANISM; EXTRACELLULAR MATRIX; GLIOBLASTOMA; GLIOMA; HUMAN; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL TIME; TUMOR INVASION; TUMOR VASCULARIZATION; BRAIN NEOPLASMS; DISEASE COURSE; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION; WHITE MATTER;

ANGIOGENESIS INHIBITORS; ANTIBODIES; BRAIN NEOPLASMS; CELL ADHESION MOLECULES; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; GLIOMA; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; SNAKE VENOMS; THALIDOMIDE; WHITE MATTER;

EID: 84961213727     PISSN: 14337398     EISSN: 1861387X     Source Type: Journal    
DOI: 10.1007/s10014-016-0261-9     Document Type: Review

References (98)

1. Penas-Prado M, Gilbert MR (2007) Molecularly targeted therapies for malignant gliomas: advances and challenges. Expert Rev Anticancer Ther 7:641–661
2. Bello L, Giussani C, Carrabba G, Pluderi M, Costa F, Bikfalvi A (2004) Angiogenesis and invasion in gliomas. Cancer Treat Res 117:263–284
3. Onishi M, Kurozumi K, Ichikawa T, Date I (2013) Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme. Neurol Med Chir (Tokyo) 53:755–763
4. Kurozumi K, Onishi M, Ichikawa T et al (2013) III. Molecular targeting therapy for glioma-bevacizumab and cilengitide. Gan To Kagaku Ryoho 40:718–722
5. Varner JA, Cheresh DA (1996) Integrins and cancer. Curr Opin Cell Biol 8:724–730
6. Varner JA, Cheresh DA (1996) Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. Important Adv Oncol 69–87
7. Wong ML, Prawira A, Kaye AH, Hovens CM (2009) Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas. J Clin Neurosci 16:1119–1130
8. Onishi M, Ichikawa T, Kurozumi K, Date I (2011) Angiogenesis and invasion in glioma. Brain Tumor Pathol 28:13–24
9. Onishi M, Ichikawa T, Kurozumi K et al (2015) Annexin A2 regulates angiogenesis and invasion phenotypes of malignant glioma. Brain Tumor Pathol 32:184–194
10. Rooprai HK, McCormick D (1997) Proteases and their inhibitors in human brain tumours: a review. Anticancer Res 17:4151–4162
11. Gumbiner BM (2005) Regulation of cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol 6:622–634
12. Nakada M, Nakada S, Demuth T, Tran N, Hoelzinger D, Berens M (2007) Molecular targets of glioma invasion. Cell Mol Life Sci 64:458–478
13. Cavallaro U, Christofori G (2004) Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 4:118–132
14. Huang Z-Y, Wu Y, Hedrick N, Gutmann DH (2003) T-cadherin-mediated cell growth regulation involves G2 phase arrest and requires p21CIP1/WAF1 expression. Mol Cell Biol 23:566–578
15. Osborn L, Hession C, Tizard R et al (1989) Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 59:1203–1211
16. Couldwell WT, de Tribolet N, Antel JP, Gauthier T, Kuppner MC (1992) Adhesion molecules and malignant gliomas: implications for tumorigenesis. J Neurosurg 76:782–791
17. Springer TA, Dustin ML, Kishimoto TK, Marlin SD (1987) The lymphocyte function associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system. Annu Rev Immunol 5:223–252
18. Stoolman LM (1989) Adhesion molecules controlling lymphocyte migration. Cell 56:907–910
19. Sasaki H, Yoshida K, Ikeda E et al (1998) Expression of the neural cell adhesion molecule in astrocytic tumors. Cancer 82:1921–1931
20. Owens GC, Orr EA, DeMasters BKK, Muschel RJ, Berens ME, Kruse CA (1998) Overexpression of a transmembrane isoform of neural cell adhesion molecule alters the invasiveness of rat CNS-1 glioma. Cancer Res 58:2020–2028
21. Prag S, Lepekhin EA, Kolkova K et al (2002) NCAM regulates cell motility. J Cell Sci 115:283–292
22. Edvardsen K, Chen W, Rucklidge G, Walsh FS, Obrink B, Bock E (1993) Transmembrane neural cell-adhesion molecule (NCAM), but not glycosyl-phosphatidylinositol-anchored NCAM, down-regulates secretion of matrix metalloproteinases. Proc Natl Acad Sci 90:11463–11467
23. Woodfin A, Voisin M-B, Nourshargh S (2007) PECAM-1: a multi-functional molecule in inflammation and vascular biology. Arterioscler Thromb Vasc Biol 27:2514–2523
24. Takada Y, Ye X, Simon S (2007) The integrins. Genome Biol 8:215
25. Hood JD, Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91–100
26. Bello L, Francolini M, Marthyn P et al (2001) Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery 49:380–389 (discussion 390)
27. Schnell O, Krebs B, Wagner E et al (2008) Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol 18:378–386
28. Brooks PC, Clark RA, Cheresh DA (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569–571
29. Kim S, Bell K, Mousa SA, Varner JA (2000) Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol 156:1345–1362
30. Kurozumi K, Ichikawa T, Onishi M, Fujii K, Date I (2012) Cilengitide treatment for malignant glioma: current status and future direction. Neurol Med Chir (Tokyo) 52:539–547
31. Novak U, Kaye AH (2000) Extracellular matrix and the brain: components and function. J Clin Neurosci 7:280–290
32. Timpl R, Brown JC (1994) The laminins. Matrix biology 14:275–281
33. Pankov R, Yamada KM (2002) Fibronectin at a glance. J Cell Sci 115:3861–3863
34. Uhm JH, Gladson CL, Rao JS (1999) The role of integrins in the malignant phenotype of gliomas. Front Biosci 4:188–199
35. Sweeney SM, Orgel JP, Fertala A et al (2008) Candidate cell and matrix interaction domains on the collagen fibril, the predominant protein of vertebrates. J Biol Chem 283:21187–21197
36. Canty EG, Kadler KE (2005) Procollagen trafficking, processing and fibrillogenesis. J Cell Sci 118:1341–1353
37. Leitinger B (2011) Transmembrane collagen receptors. Annu Rev Cell Dev Biol 27:265–290
38. Khoshnoodi J, Pedchenko V, Hudson BG (2008) Mammalian collagen IV. Microsc Res Tech 71:357–370
39. Ogawa K, Oguchi M, Nakashima Y, Yamabe H (1989) Distribution of collagen type IV in brain tumors: an immunohistochemical study. J Neurooncol 7:357–366
40. Senner V, Ratzinger S, Mertsch S, Grässel S, Paulus W (2008) Collagen XVI expression is upregulated in glioblastomas and promotes tumor cell adhesion. FEBS Lett 582:3293–3300
41. Bauer R, Ratzinger S, Wales L et al (2011) Inhibition of collagen XVI expression reduces glioma cell invasiveness. Cell Physiol Biochem 27:217–226
42. Rutka JT, Apodaca G, Stern R, Rosenblum M (1988) The extracellular matrix of the central and peripheral nervous systems: structure and function. J Neurosurg 69:155–170
43. Giese A, Rief MD, Loo MA, Berens ME (1994) Determinants of human astrocytoma migration. Cancer Res 54:3897–3904
44. Deryugina EI, Bourdon MA (1996) Tenascin mediates human glioma cell migration and modulates cell migration on fibronectin. J Cell Sci 109:643–652
45. Zagzag D, Friedlander DR, Dosik J et al (1996) Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. Cancer Res 56:182–189
46. Zagzag D, Shiff B, Jallo GI et al (2002) Tenascin-C promotes microvascular cell migration and phosphorylation of focal adhesion kinase. Cancer Res 62:2660–2668
47. Mahesparan R, Read T-A, Lund-Johansen M, Skaftnesmo K, Bjerkvig R, Engebraaten O (2003) Expression of extracellular matrix components in a highly infiltrative in vivo glioma model. Acta Neuropathol 105:49–57
48. Gatson NN, Chiocca EA, Kaur B (2012) Anti-angiogenic gene therapy in the treatment of malignant gliomas. Neurosci Lett 527:62–70
49. Nishimori H, Shiratsuchi T, Urano T et al (1997) A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene 15:2145–2150
50. Nakada M, Nakamura H, Ikeda E et al (1999) Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. Am J Pathol 154:417–428
51. Duda D, Sunamura M, Lozonschi L et al (2002) Overexpression of the p53-inducible brain-specific angiogenesis inhibitor 1 suppresses efficiently tumour angiogenesis. Br J Cancer 86:490–496
52. Kudo S, Konda R, Obara W et al (2007) Inhibition of tumor growth through suppression of angiogenesis by brain-specific angiogenesis inhibitor 1 gene transfer in murine renal cell carcinoma. Oncol Rep 18:785–791
53. Kaur B, Brat DJ, Devi NS, Van Meir EG (2005) Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. Oncogene 24:3632–3642
54. Kaur B, Cork SM, Sandberg EM et al (2009) Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. Cancer Res 69:1212–1220
55. Hardcastle J, Kurozumi K, Dmitrieva N et al (2010) Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Mol Ther 18:285–294
56. Yoo JY, Haseley A, Bratasz A et al (2012) Antitumor efficacy of 34.5 ENVE: a transcriptionally retargeted and “Vstat120”-expressing oncolytic virus. Mol Ther 20:287–297
57. Kurozumi K, Hardcastle J, Thakur R et al (2008) Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol Ther 16:1382–1391
58. Kurozumi K, Hardcastle J, Thakur R et al (2007) Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 99:1768–1781
59. Fujii K, Kurozumi K, Ichikawa T et al (2013) The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus. Cancer Gene Ther 20:437–444
60. Leask A, Abraham DJ (2006) All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 119:4803–4810
61. Li J, Ye L, Owen S, Weeks HP, Zhang Z, Jiang WG (2015) Emerging role of CCN family proteins in tumorigenesis and cancer metastasis (Review). Int J Mol Med 36:1451–1463
62. Ishida J, Kurozumi K, Ichikawa T et al (2015) Evaluation of extracellular matrix protein CCN1 as a prognostic factor for glioblastoma. Brain Tumor Pathol 32:245–252
63. Haseley A, Boone S, Wojton J et al (2012) Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma. Cancer Res 72:1353–1362
64. Kireeva ML, Lam SC, Lau LF (1998) Adhesion of human umbilical vein endothelial cells to the immediate-early gene product Cyr61 is mediated through integrin alphavbeta3. J Biol Chem 273:3090–3096
65. Iozzo RV, Schaefer L (2015) Proteoglycan form and function: a comprehensive nomenclature of proteoglycans. Matrix Biol 42:11–55
66. Wu YJ, La Pierre DP, Jin W, Albert JY, Burton BY (2005) The interaction of versican with its binding partners. Cell research 15:483–494
67. Silver DJ, Siebzehnrubl FA, Schildts MJ et al (2013) Chondroitin sulfate proteoglycans potently inhibit invasion and serve as a central organizer of the brain tumor microenvironment. J Neurosci 33:15603–15617
68. Hu F, a Dzaye OD, Hahn A et al (2015) Glioma-derived versican promotes tumor expansion via glioma-associated microglial/macrophages Toll-like receptor 2 signaling. Neuro Oncol 17:200–210
69. Heckmann D, Kessler H (2007) Design and chemical synthesis of integrin ligands. Methods Enzymol 426:463–503
70. Meyer A, Auernheimer J, Modlinger A, Kessler H (2006) Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr Pharm Des 12:2723–2747
71. Tabatabai G, Weller M, Nabors B et al (2010) Targeting integrins in malignant glioma. Target Oncol 5:175–181
72. Leavesley DI, Ferguson GD, Wayner EA, Cheresh DA (1992) Requirement of the integrin beta 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen. J Cell Biol 117:1101–1107
73. MacDonald TJ, Stewart CF, Kocak M et al (2008) Phase I clinical trial of cilengitide in children with refractory brain tumors: pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol 26:919–924
74. MacDonald TJ, Taga T, Shimada H et al (2001) Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 48:151–157
75. Onishi M, Kurozumi K, Ichikawa T et al (2013) Gene expression profiling of the anti-glioma effect of Cilengitide. Springerplus 2:160
76. Brooks PC, Montgomery AM, Rosenfeld M et al (1994) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157–1164
77. Onishi M, Ichikawa T, Kurozumi K et al (2013) Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models. Neuropathology 33:162–174
78. Tate MC, Aghi MK (2009) Biology of angiogenesis and invasion in glioma. Neurotherapeutics 6:447–457
79. Ishida J, Onishi M, Kurozumi K et al (2014) Integrin inhibitor suppresses bevacizumab-induced glioma invasion. Transl Oncol 7(292–302):e291
80. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL (2002) Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 62:4263–4272
81. Abdollahi A, Griggs DW, Zieher H et al (2005) Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 11:6270–6279
82. Tentori L, Dorio AS, Muzi A et al (2008) The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. Oncol Rep 19:1039–1043
83. Reardon DA, Fink KL, Mikkelsen T et al (2008) Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26:5610–5617
84. Mikkelsen T, Brodie C, Finniss S et al (2009) Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer 124:2719–2727
85. Shimazu Y, Kurozumi K, Ichikawa T et al (2015) Integrin antagonist augments the therapeutic effect of adenovirus-mediated REIC/Dkk-3 gene therapy for malignant glioma. Gene Ther 22:146–154
86. Eskens FA, Dumez H, Hoekstra R et al (2003) Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 39:917–926
87. Stupp R, Van Den Bent M, Erridge S, et al. (2010) Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: protocol of a multicenter, randomized, open-label, controlled phase III trial (CENTRIC). ASCO Annual Meeting Proceedings. p TPS152
88. Nabors LB, Fink KL, Mikkelsen T et al (2015) Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro Oncol 17:708–717
89. Weller M, Nabors L, Gorlia T et al (2016) Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. Oncotarget. [Epub ahead of print]
90. Mason WP (2015) End of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma. Neuro Oncol 17:634–635
91. D’Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 91:4082–4085
92. Hansen JM, Harris C (2004) A novel hypothesis for thalidomide-induced limb teratogenesis: redox misregulation of the NF-κB pathway. Antioxid Redox Signal 6:1–14
93. Fine HA, Figg WD, Jaeckle K et al. (2000) Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18:708–715
94. Giglio P, Dhamne M, Hess KR et al (2012) Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer 118:3599–3606
95. Bigner DD, Brown M, Coleman RE et al (1995) Phase I studies of treatment of malignant gliomas and neoplastic meningitis with131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab′) 2-a preliminary report. J Neurooncol 24:109–122
96. Reardon DA, Akabani G, Coleman RE et al (2002) Phase II trial of murine 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20:1389–1397
97. Reulen H-J, Poepperl G, Goetz C et al (2015) Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy. J Neurosurg 123:760–770
98. ClinicalTrials.gov: registry and results database of federally and privately supported clinical trials. http://clinicaltrials.gov/ct2/home. Accessed 24 Feb 2016